GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » 3-Year EPS without NRI Growth Rate

Oncopeptides AB (OSTO:ONCO) 3-Year EPS without NRI Growth Rate : 52.40% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB 3-Year EPS without NRI Growth Rate?

Oncopeptides AB's EPS without NRI for the three months ended in Dec. 2023 was kr-0.64.

During the past 3 years, the average EPS without NRI Growth Rate was 52.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Oncopeptides AB was 52.40% per year. The lowest was -96.30% per year. And the median was -58.40% per year.


Competitive Comparison of Oncopeptides AB's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Oncopeptides AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncopeptides AB's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's 3-Year EPS without NRI Growth Rate falls into.



Oncopeptides AB 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Oncopeptides AB  (OSTO:ONCO) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Oncopeptides AB 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncopeptides AB (OSTO:ONCO) Business Description

Industry
Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB (OSTO:ONCO) Headlines